Company intelligence / Profile preview

hemotune

Schlieren, Zurich, Switzerlandhemotune.ch ↗

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

hemotune is developing a precision medicine, multi-target blood purification system using nanoengineered magnetic beads. The lead program aims to restore immune balance in patients with sepsis-induced immunosuppression and septic shock. Clinical trials are being prepared or initiated for the HemoSystem device, but no published clinical results are available yet.

Therapeutic areas: Infectious Diseases
Modalities: DeviceNanoparticle (nanoengineered magnetic beads)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

HemoSystem

Pre-clinical

Indications: Sepsis, Septic shock

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on hemotune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hemotune.

Explore the full profile